Table 3

Case report of patients with cardiac complications

CHDAge at pregnancy (years)SaturationNYHAPulmonary pressures (mm Hg)Subaortic ventricular functionSubpulmonary ventricular functionTreatment during pregnancyPregnancy duration (WG)Cardiac event/treatmentTerm at cardiac eventPeriod of event
1Isolated VSD31851115/60/85NormalNormalSildenafil (30 mg ×3/day)30Hypoxaemia (64%)/bed rest and oxygen therapyThird trimester and early PP2015
2DORV+aortic coarctation (diagnosed during pregnancy)21802Not availableNormalNormalNo31Cardiogenic shock following CS indicated for severe pre-eclampsia/inotropic drugs, inhaled NO+sildenafil and ventricular assistance deviceEarly PP2011
3Pulmonary atresia+VSD+collaterals3080280/45/60NormalNormalNone31Heart failure/diureticsThird trimester2001
4PDA32832Not availableUKUKOxygen therapy32Hypoxaemia, pulmonary hypertensive crisis and cardiogenic shock/inotropic treatmentEarly PP2002
5Isolated ASD4276290/52/65NormalModerately impairedUFH28Hypoxaemia, pulmonary hypertensive crisis and heart failure, death/inotropic drugs, prostacyclin+NO and UFHEarly PP2004
6DORV+aortic coarctation2274370/55/39NormalNormalTadalafil, AVK relayed by UFH29Hypoxaemia (60%)/bed rest and oxygen therapyEarly PP2013
  • Invasive and non-invasive pulmonary pressures were not available in two patients.

  • ASD, atrial septal defect; CHD, congenital heart disease; CS, caesarian section; DORV, double outlet right ventricle; NO, nitric oxide; NYHA, New York Heart Association; PDA, patent ductus arteriosus; PP, postpartum; UFH, unfractioned heparin; UK, unknown; VSD, ventricular septal defect; WG, weeks of gestation.